top of page

Guidance on Development and Submission of Near Infrared Analytical Procedures– USFDA

US Food and Drug Administration (FDA) on 06-July-2021, finalized guidance on “Development and Submission of Near Infrared Analytical Procedures” which provides recommendations to applicants to aid the development, validation, and use of near infrared (NIR)-based analytical procedures in evaluating the identity, strength, quality, purity, and potency of drug substances and drug products.

The recommendations apply to

  • New drug applications (NDAs),

  • Abbreviated new drug applications (ANDAs),

  • Supplemental NDAs and ANDAs for small molecule drugs.

  • The principles in this guidance also apply to drug substances and drug products covered in Type II drug master files.

  • This guidance provides recommendations to applicants for applying the concepts described in the guidance for industry PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (September 2004) (PAT guidance) and the International Council for Harmonisation (ICH) guidance for industry Q2(R1) Validation of Analytical Procedures: Text and Methodology (November 2005) to NIR analytical procedures that use chemometric models.

  • This guidance also provides recommendations for submitting NIR documentation in applications.

FDA intends to issue recommendations specific to NIR methods used for biological products under biologics license applications in a future revision to this guidance.


This guidance pertains only to the development and validation of NIR analytical procedures and does not provide recommendations concerning the setup, qualification, maintenance, or calibration of NIR instruments. Although this guidance specifically addresses NIR spectroscopy, this guidance’s concepts of validation can be applied to other process analytical technologies

Comments


bottom of page